Clinical–Alimentary TractSerious lower gastrointestinal clinical events with nonselective NSAID or coxib use☆
References (0)
Cited by (338)
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain
2023, Pharmacology and TherapeuticsEthosuximide improves chronic pain-induced anxiety- and depression-like behaviors
2019, European NeuropsychopharmacologyCitation Excerpt :Chemotherapy-induced neuropathy have no treatment (Hershman et al., 2014; Poupon et al., 2015). Current drugs for the management of rheumatoid arthritis (Smolen et al., 2017) have also a limited effect on pain and entail serious adverse effects (Boyman et al., 2014; Laine et al., 2003; Solomon et al., 2017). Clearly, innovative treatments are needed to reduce pain and comorbidities in chronic pain patients and thereby to improve their quality of life.
Points to consider in the management of old rheumatologic patients
2019, Revue du Rhumatisme MonographiesLower Gastrointestinal Bleeding
2019, Clinical Gastrointestinal EndoscopyAre NSAIDs Double Trouble? <sup>∗</sup>
2018, Journal of the American College of Cardiology
- ☆
Supported by Merck & Co., Whitehouse Station, New Jersey. Dr. Laine received research support from Merck, and is a consultant for Merck, Pharmacia, Novartis, and Pfizer. Dr. Hawkey has received research funding from AstraZeneca, Alizyme, Boehringer Ingelheim, GlaxoSmithKline, Merck, NicOx, Novartis, and Pfizer. Dr. Schnitzer is a consultant for AstraZeneca, GlaxoSmithKline, McNeil Consumer, Merck, and Novartis, and has received research support from AstraZeneca, Merck, and Novartis. Dr. Bombardier is a consultant for Merck Research Laboratories, Schering Canada, and Wyeth Ayerst Research, has received research grants from Abbott Laboratories (formerly Knoll Pharmaceutical Company), Aventis Pharmaceuticals, and Merck Research Laboratories, and is a member of the Advisory Board for Abbot Laboratories, Bristol-Myers Squibb Company, and Merck Frosst Canada.